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Introduction
The role of the immune system in recognizing and controlling 
tumor growth is well supported (1). Key evidence over the past 
decade from mouse models and human cancer patients has shown 
that the immune system recognizes transformed cells, and now it 
is generally accepted that avoiding immune detection and elimina-
tion is a hallmark of cancer (2). Conversely, the immune system can 
also promote tumor progression by supporting chronic inflamma-
tion, shaping tumor immunogenicity, and suppressing antitumor 
immunity. This dual role of the immune system in suppressing or 
promoting tumor growth is termed cancer immunoediting and 
consists of three phases: elimination, equilibrium, and escape (1).
In this Review, we provide a brief summary of the three phases 
of cancer immunoediting. We then describe the characteristics of an 
adaptive immune resistance tumor microenvironment that impacts 
survival outcome including its makeup (immune contexture), the 
distilled prognostic histological score (immunoscore), and the pres-
ence of tertiary lymphoid structures (TLSs). Mouse and human stud-
ies support the cancer immunoediting role of CD8+ T cells in this 
type of tumor microenvironment, as opposed to others, and we also 
discuss the role of other immune cells and factors in influencing the 
function of effector CD8+ T cells in this context. Finally, we discuss 
the temporal occurrence of cancer immunoediting in metastases 
and whether it differs from its primary tumor of origin.
The three Es of cancer immunoediting: 
immunity shaping tumor immunogenicity
Elimination. In the elimination phase, innate and adaptive immu-
nity work together to destroy developing tumors long before they 
become clinically apparent. Although the elimination phase has 
not been directly visualized in vivo, studies have demonstrated that 
immunodeficient mice (deficient for effector molecules such as 
IFNs and perforin; recognition pathways like NKG2D; or cell types 
such as T and NK cells) displayed earlier onset or greater pene-
trance of carcinogen-induced and spontaneous cancers compared 
with that seen in WT mice (reviewed in refs. 1, 3–6).
Equilibrium. Rare tumor cell variants not destroyed in the 
elimination phase can proceed into the equilibrium phase, where 
their outgrowth is prevented by immunologic mechanisms. In a 
2007 study (7), WT mice treated with low-dose methylcholan-
threne (MCA) were demonstrated to harbor occult cancer cells 
that adaptive immunity (e.g., T cells and IFN-γ) kept in check. A 
subsequent study (8) demonstrated that immune-mediated tumor 
dormancy was dictated by a balance between two opposing cytok-
ines, IL-12 and IL-23 (9), and could last for much of the lifespan of 
a mouse. The existence of the equilibrium phase was additionally 
supported by observations in mice with p53-mutant tumors (8) 
and by two other studies in which a Th1 environment dictated the 
eventual outcome of dormant tumors (10, 11).
Escape. When tumors circumvent immune recognition and/
or destruction, they progress from the equilibrium to the escape 
phase, where they become clinically apparent. Tumors escape due 
to changes in their response to immunoselection pressures and/or 
to increased tumor-induced immunosuppression or immune sys-
tem deterioration. The mechanisms of tumor cell escape can be 
classified into three categories, as shown in Figure 1. Over the past 
two decades, these pathways have been the subjects of intense 
investigation, with the aim of developing new cancer immuno-
therapies (reviewed extensively in refs. 1, 3, 5).
Regarding tumor editing in each of these three phases, tumors 
derived from immunodeficient mice were found to be more immu-
nogenic than were similar tumors derived from immunocompetent 
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sively reviewed and summarized (5). More specifically, early proof 
for the elimination phase of cancer immunoediting in humans also 
comes with the observation that clonal T cells were expanded in 
patients with spontaneously regressing melanoma lesions (13–15). 
Moreover, the presence of tumor-infiltrating CD8+ T cells and a 
Th1 immune signature is prognostic of improved disease-free sur-
vival (DFS) and overall survival (OS) compared with the classical 
tumor-node-metastasis (TMN) staging (5, 16). This information 
is captured at the stage of tumor escape, but predicts the ability of 
the natural immune reaction or therapies to drive the human tumor 
into an equilibrium or, indeed, eliminate the tumor altogether. Criti-
cally, the recent success of immune checkpoint inhibitors (e.g., anti–
CTLA-4 and anti–PD-1/–PD-L1) in the clinic (17) further demon-
strates that cancer immunoediting occurs in patients with advanced 
cancers and that this process can be reset by therapy.
Immune contexture, immunoscore, and TLS: 
influencing survival outcome
A central feature of cancer immunoediting is that tumors express 
antigens (tumor-associated antigens [TAAs] or tumor-specific 
mice (1). Although T cells were inferred to sculpt tumor immuno-
genicity, it was unclear whether antigens expressed by emerging 
nascent tumor cells were recognized by T cells and could then be 
subsequently modulated in response to selection pressure. A study 
using an exome-sequencing approach demonstrated that sarcoma 
cells derived from MCA-inoculated mice expressed immunodom-
inant neoantigens that could be immunoedited by CD8+ T cells, 
leading to tumor escape (12). Thus, the outgrowth of tumor cells 
lacking these strong antigens represents one mechanism of cancer 
immunoediting.
Cancer immunoediting: from mice to humans
The process of cancer immunoediting is obviously more difficult to 
assess in humans, given that they are an outbred population living in 
an uncontrolled environment; therefore, there are few examples of 
viable, specific immune gene loss (5). Nevertheless, the earliest clin-
ical data supporting the immunoediting process in humans, includ-
ing data from patients with severe immunodeficiencies, receiving 
organ transplants, spontaneously rejecting their tumors, or produc-
ing tumor-associated, antigen-specific antibodies, have been exten-
Figure 1. Major mechanisms of tumor escape and therapeutic options. The mechanisms of tumor cell escape can be classified into three major categories: 
(A) reduced immune recognition and immune cell stimulation through downregulation or loss of strong tumor antigens and antigen-presenting machin-
ery or lack of costimulatory molecules; (B) upregulation of resistance mechanisms against the cytotoxic effectors of immunity (e.g., STAT3) or increased 
expression of prosurvival or growth factor genes (e.g., Bcl-2, Her2/neu); and (C) establishment of an immunosuppressive tumor microenvironment via (a) 
production of cytokines (e.g., VEGF, TGF-β) and metabolic factors (e.g., adenosine, PGE2); (b) induction and/or recruitment of Tregs and MDSCs; or (c) induc-
tion of adaptive immune resistance through ligation of inhibitory receptors (e.g., CTLA-4, PD-1, Tim-3) on immune effector cells. Over the past two decades, 
strategies to target these pathways have been the subject of intense investigation, and some of these are listed in the figure. iNOS, inducible NOS.
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microenvironment (Figure 2). In tumors, all types of immune 
cells can be found in various proportions and locations. They 
include myeloid cells, B cells, and all subsets of T cells (refs. 16, 
18, and discussed in further detail below).
Immunoscore. The “immunoscore” is a scoring system derived 
from the immune contexture (16, 19, 20) and is a clinically useful 
prognostic marker (21) based on the enumeration of two lympho-
cyte populations (CD3 and CD8), in both the core of the tumor 
(CT) and in the invasive margin (IM) of tumors. The immunos-
core provides a score ranging from immunoscore 0, in which low 
densities of both cell types are found in both regions, to immuno-
score 4, in which high densities are found in both regions. Immu-
noscore classification was shown to have a prognostic significance 
in all stage I, II and III patients with colorectal cancer (CRC) that 
was superior to that of the American Joint Committee on Cancer/
Union for International Cancer Control (AJCC/UICC) TNM (T 
stage, N stage, and tumor differentiation) classification system 
(22, 23). Tumor invasion was shown to be statistically dependent 
on the host’s immune reaction. It is believed that the ability of 
effector memory T cells to recall previously encountered antigens 
mutant antigens [TSMAs]) that can be recognized by T cells, 
resulting in their eventual destruction and/or selection of tumor 
escape clones. As such, the importance of T cells, in particular 
CD8+ T cells, in cancer immunoediting has been demonstrated 
in many preclinical mouse models of cancer (5). In humans, large 
annotated data sets have since demonstrated the presence of 
infiltrating CD8+ T cells in tumors. In this section of the Review, 
we discuss immune contexture, immunoscore, and the presence 
of tumor-adjacent TLSs that can predict patient survival and 
responses to immunotherapy (16).
Immune contexture. The immune contexture of human can-
cers defines a complex immunologic tumor microenvironment 
in which the location, density, and functional orientation of infil-
trating hematopoietic cells correlate with the clinical outcome 
of patients (reviewed extensively in ref. 16). In most cancers, a 
strong infiltration of memory CD8+ T cells and a Th1 orientation 
correlated with a favorable prognosis in terms of progression-free 
survival (PFS) and/or OS (ref. 16 and Figure 2). Other parameters 
such as immune cells, cytokines, chemokines, and other factors 
also influence the generation of a clinically efficient immune 
Figure 2. The immune contexture of the tumor 
microenvironment as a prognostic marker for 
long-term survival. (A) Cellular components of 
the tumor stroma include blood and lymphatic 
vessels, infiltrating and resident leukocytes, vari-
ous populations of fibroblasts, and mesenchymal 
support cells unique to each tissue environment. 
The immune contexture is defined as the type, 
density, functional orientation, and location of 
immune cells within distinct tumor regions. A 
spectrum of soluble cytokines and chemokines 
regulate the entry of immune cells into tumors, 
which then have different effects on tumor pro-
gression. All types of immune cells are present 
in the tumor, including macrophages, DCs, mast 
cells, NK cells, naive and memory lymphocytes, 
B cells, and effector T cells (including various 
subsets of T cells: Th cells, Th1, Th2, Th17, Tregs, 
Tfh, and CTLs). Immune cells can be located in 
the core of the tumor, in the invasive margin, or 
in the adjacent TLSs. Few CD8+ T cells are seen 
in human TLSs, which are similar to secondary 
follicles in lymph nodes. TLSs contain naive and 
memory T cells, Tfh cells, B cells, and mature 
DCs. FDC, follicular DC. (B) High expression levels 
of various immune parameters that define a 
Th1 immune contexture, as well as the presence 
of Tfh cells, B cells, CXCL13, IL-21, and IL-15, are 
associated with prolonged DFS and/or improved 
OS in CRC (figures adapted from refs. 16, 23).
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Tumors displaying an adaptive immune 
resistance microenvironment
Although a strong infiltration of CD8+ T cells and a Th1 orientation 
correlated with favorable prognosis in terms of DFS and OS, their 
effector function in tumors can be blunted through various immu-
nosuppressive strategies mediated by tumors (43). One mechanism, 
termed adaptive immune resistance, represents the attempt of can-
cer cells to evade the immune system (44, 45). During this process, 
recognition of tumor cells by activated T cells results in the produc-
tion of IFN-γ. This upregulates PD-L1 (B7-H1) on tumor cells and 
tumor-infiltrating immune cells and binds it to PD-1, an inhibitory 
immune checkpoint receptor expressed on activated T cells to atten-
uate their effector function. These receptors are normally used for 
maintaining self-tolerance and modulating the duration and ampli-
tude of the physiological immune response but have been hijacked 
by tumors as a means of avoiding immune destruction. Indeed, 
high levels of PD-L1 on tumor-associated myeloid cells and drain-
ing lymph node DCs (46) and B7-H4 (another B7 family member) 
on macrophages (47) are important immune escape mechanisms 
in human cancers. It is now clear that engagement of checkpoint 
receptors on activated CD8+ T cells represents a major mecha-
nism of tumor-induced immunosuppression. Indeed, over the 
past five years, immune checkpoint inhibitors anti–CTLA-4 (ipili-
mumab), anti–PD-1 (pembrolizumab, nivolumab), and anti–PD-L1 
(MPDL3280A) have had remarkable success in inducing durable 
clinical responses across a broad spectrum of malignancies (29, 31, 
48–50) and have revolutionized the field of cancer immunology. 
PD-1/PD-L1 blockade is thought to operate predominantly in the 
tumor microenvironment, since PD-L1 ligand is commonly overex-
pressed by tumor cells and myeloid cells within human tumors (50); 
in comparison, CTLA-4 and its ligands are not as tumor localized.
The respective roles of malignant cells and the host in shap-
ing the tumor/immune contexture is beginning to be uncovered 
by analysis of cancer subgroups based on immune microenviron-
ments that are defined by PD-L1 expression and the presence of 
tumor-infiltrating lymphocytes (TILs). On the basis of the observa-
tion that patients’ responses to anti–PD-1 were significantly associ-
ated with PD-1 expression on TILs and PD-L1 expression on tumor 
cells (44, 51, 52), Taube et al. proposed stratifying the tumor micro-
environment into four types. Type 1 is PD-L1 positive, with TILs 
driving adaptive immune resistance; type II is PD-L1 negative, with 
no TILs, indicating immune ignorance; type III is PD-L1 positive, 
with no TILs, indicating intrinsic induction; and type IV is PD-L1 
negative, with TILs, indicating the role of other suppressor(s) in 
promoting immune tolerance. PD-L1 can also be expressed con-
stitutively on cancer cells through poorly characterized oncogenic 
signaling pathways (53, 54), and type I and III tumor microenviron-
ments may include such tumor cells. For the rest of this Review, we 
will discuss the role of cancer immunoediting in tumors with the 
type I adaptive immune resistance phenotype, given that evidence 
for cancer immunoediting in this subgroup is strongest.
Cancer immunoediting in tumors with an 
adaptive immune resistance phenotype
Since Taube’s initial stratification, clinical studies have gone on 
to further define the immune profile of patients who respond 
to therapies targeting the PD-1/PD-L1 pathway. While tumor 
and traffic into tumors may lead to long-term immunity in human 
cancer (24, 25). Now, a clinical validation of the immunoscore 
with standardized procedures is necessary to reach clinical appli-
cability for individual patients with CRC and other cancers (26, 
27). The immunoscore also provides a tool and targets for novel 
therapeutic approaches, including immunotherapy (as recently 
illustrated in clinical trials boosting T cell responses with anti–
CTLA-4, anti–PD-1, and anti–PD-L1) (28–31).
Tumor-adjacent TLSs. In situations of chronic stimulation 
of the immune system, such as in autoimmune and inflamma-
tory diseases or in transplanted organs, organized lymphoid 
structures can form in these pathological locations, display-
ing all characteristics of the immunity-generating sites of sec-
ondary lymphoid organs (reviewed in ref. 32). These TLSs can 
represent a very powerful means to generate effective, local 
immune reactions. In fact, they precede the appearance of 
lymph nodes in evolution (33), and lung viral infections can be 
eradicated by local TLSs in lymph node–deficient mice (34). 
TLSs are consistently found in the tumor microenvironment of 
most human cancers (32).
TLSs are composed of a T and a B cell zone, where T cells are 
in contact with mature DCs, whereas B cells interact with follic-
ular DCs. These TLSs are surrounded by peripheral lymph node 
addressin–expressing high endothelial venules (HEVs), which are 
likely sites of entry of naive lymphocytes from the blood. All lym-
phocytes in TLSs express the peripheral lymph node addressin 
(PNAd) receptor CD62-L. Naive T cells are likely instructed by 
contacting DCs presenting TAAs and central memory and effec-
tor memory T cells, all of which are found in TLSs. In tumors, B 
cells are almost exclusively found in TLS germinal centers, where 
they express the somatic hypermutation and switch recombina-
tion enzyme activation-induced cytidine deaminase (AICDA). 
Plasma cells are seen at the periphery of the TLS and have been 
reported to produce antitumor-specific antigens in non–small-
cell lung cancer (NSCLC) (35). One can therefore hypothesize 
that efficient antitumor reactions can be generated within TLSs, 
where DCs instruct lymphocytes, which, having entered directly 
through HEVs, escape the suppressive milieu of the tumor micro-
environment (32).
TLSs appear to play a role in the anticancer immune response. 
Indeed, in melanoma, breast, lung, and colorectal carcinomas, 
high densities of TLSs have been reported to correlate with a 
favorable prognosis (36). Strikingly, TLSs are induced in cervical 
carcinomas (37) or pancreatic ductal cancer (38) upon vaccination 
with TSMAs. That TLSs are necessary for generating clinically 
efficient immune reactions is supported by the fact that a high 
density of CD8+ T cells is associated with longer patient survival 
when tumors display high TLS densities in lung (39), colorectal 
(40), and renal cell cancers (41). By contrast, they correlate with 
shorter survival in lung (39) and clear cell renal cell carcinoma (41) 
with low numbers of intratumoral TLSs. Recently, the presence 
of TLSs has been reported in some breast cancers, which sug-
gests the presence of organized immunity and the generation of 
memory B cells within the tumor (42). Therefore, identification, 
enumeration, and structural analyses of TLSs are useful tools to 
predict patient prognosis and immunotherapy follow-up, but also 
to identify tumor-specific clones of T and B cells.
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expressed a number of TAAs (NY-ESO-1, MAGE-C1, and Melan-A) 
prior to immunization with an NY-ESO-1 vaccine (62). In another 
case report, analyses of three consecutive lesions obtained within 
one year of a patient’s developing stage IV melanoma revealed a 
gradual loss of immunogenicity that culminated in complete T cell 
resistance of the tumor cells caused by an irreversible HLA  class I–
negative phenotype (63). Overall, these studies provide evidence 
that tumors can express antigens recognizable by CD8+ T cells and 
that they are critical in the immunoediting of tumors with an adap-
tive immune resistance phenotype.
Does cancer immunoediting occur in epithelial cancers? Many 
of the principles of cancer immunoediting were proposed and 
demonstrated in mice using the chemically induced MCA sar-
coma model (7, 64). These sarcomas are considered immunogenic 
and have a high mutational load similar to that of ultraviolet- and 
other carcinogen-induced human cancers (12). As such, a com-
mon criticism for the cancer immunoediting hypothesis is a lack of 
evidence that it holds true for epithelial cancers caused by simple 
drivers, which often have a lower mutational load (65). This may 
significantly limit the number of neoantigens capable of being 
presented on the tumor’s HLA class I alleles.
There is now increasing evidence to support the occurrence of 
cancer immunoediting in epithelial cancers. Recently, genetic find-
ings provided evidence for immunoediting in tumors and uncov-
ered mechanisms of tumor-intrinsic resistance to cytolytic activity 
(66). In a patient with metastatic cholangiocarcinoma, a cancer with 
a low mutational load, researchers detected the presence of a spe-
cific CD4+ T cell recognizing a mutation in the ERBB2-interacting 
protein (ERBB2IP)(67). Similarly, high levels of CD8+PD-1+ T cells 
have been observed in small numbers of patients with CRC-MSS, 
who generally have a lower mutational load, suggesting that good 
T cell neo-epitopes can be generated if the mutations are appropri-
ately positioned (57). Epithelial ovarian cancer (EOC), classically 
thought to be a nonimmunogenic cancer, provides further exam-
ples of cancer immunoediting (68), including tumor-specific CD8+ 
T cells that recognize mutated oncogenes such as HER2 (69). An 
increasing number of large breast cancer data sets have reported 
the correlation of T cell infiltrates with better clinical outcomes, 
including in HER2-positive breast cancer patients, for whom an 
association between immunity and better survival after treatment 
with chemotherapy and anti-HER2 therapies has been reported 
(42). High levels of T cell checkpoint receptors have also been 
detected in HER2-overexpressing breast cancer at the mRNA level 
as well as in triple-negative breast cancer (TNBC) (70). Anti-HER2 
and anti–PD-1 have been shown to be synergistic in mouse models 
(71), and recently, anti–PD-1 (pembrolizumab) demonstrated clini-
cal activity in TNBC (72). This potentially opens up new treatment 
avenues for patients with breast cancer.
Other parameters impacting CD8+ T cells in 
cancer immunoediting
We now discuss how the presence of immune cells and other 
parameters modulate the positive clinical impact of memory CD8 
T cells and affect their efficacy as potential antitumor effector cells.
Myeloid cells. In general, high densities of myeloid cells, i.e., mac-
rophages and myeloid-derived suppressor cells (MDSCs), correlate 
with poor prognosis (73). When it has been characterized, it appears 
expression of PD-L1 was thought to be an indicator of response, 
Herbst et al. demonstrated that PD-L1 expression on immune 
cells (particularly myeloid) in different cancers (NSLC, renal cell 
carcinoma [RCC], melanoma, head and neck squamous cell car-
cinoma [HNSCC], gastric cancer, CRC, pancreatic cancer) was 
also a key predictor of clinical activity (50, 52), adding further 
complexity (45). Tumeh et al. also determined that the pretreat-
ment number of IM PD-1–expressing CD8+ T cells correlated with 
clinical responses in metastatic melanoma patients treated with 
anti–PD-1 (pembrolizumab) (52). This suggested the presence of 
a specific immune response to tumor antigens. Using next-gener-
ation sequencing, they demonstrated that pretreated CD8+ T cells 
had a more restricted T cell receptor β  (TCRβ) chain usage, indi-
cating that clonality correlated with clinical response to anti–PD-1 
(52). This validates a previous study showing that PD-1 identified 
patient-specific CD8+ tumor-reactive T cells infiltrating human 
melanoma (55). Similar observations were also made in a subgroup 
of CRC patients who displayed microsatellite instability (MSI) 
characterized by a high number of neoantigens as a consequence 
of a DNA repair defect (56). This subgroup displayed the adaptive 
immune resistance phenotype characterized by a high infiltra-
tion of T cells, particularly CD8+ T cells, and these patients had 
a good prognosis with few metastases (57, 58). This observation 
was recently confirmed by Llosa et al., who reported that almost 
all CRCs with MSI (CRC-MSI), but not microsatellite stable (MSS) 
CRC (CRC-MSS), displayed high infiltration with activated CD8+ 
cytotoxic T lymphocytes (CTLs) and activated Th1 cells charac-
terized by IFN-γ production and the Th1 transcription factor T-bet 
(57). Interestingly, the upregulation of multiple immune check-
points (PD-1, Tim-3, LAG-3, CTLA-4, IDO) was only found in 
CRC-MSI patients. This may explain why MSI tumors are not nat-
urally eliminated, despite an immune-promoting Th1/CTL micro-
environment. Given this compelling evidence, two clinical trials 
(ClinicalTrials.gov identifiers NCT01876511 and NCT02060188) 
have commenced in order to test the efficacy of anti–PD-1 in CRC 
patients stratified by their MSI status (57).
Neoantigen discovery. While a number of TAAs have been iden-
tified since the 1990s (e.g., NY-ESO-1, MAGE), TSMAs have been 
harder to discover due to the labor-intensive process required to 
identify them. However, with advances in genomics and bioin-
formatics technology, a number of recent studies in mice and 
humans have identified TSMAs (59, 60). These studies further 
strengthen the idea that “passenger” mutations as opposed to 
“driver” mutations (which contribute directly to cancer initiation 
and progression) can function as neoantigens that induce tumor 
immunity before or after therapeutics such as ipilimumab. Using 
the same MCA-induced tumor model that Matsushita et al. used 
to study immunoediting of immunodominant neoantigens by 
CD8+ T cells (12), Gubin et al. showed that even escape tumors 
harbor TSMA-recognizing T cells, but are inhibited by immune 
checkpoints (PD-1 and CTLA-4) (59). Such TSMAs can act as ther-
apeutic vaccines, as evidenced by their ability to cause established 
tumor rejection with an efficacy similar to that of immune check-
point blockade therapy in tumor-bearing mice. Given the hetero-
geneity of tumors (61), it would be wise to vaccinate with a number 
of TSMAs, if possible, to reduce the emergence of escape variants. 
This is illustrated in a case report of a patient with melanoma who 
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that the negatively impacting macrophages are of the M2 pheno-
type (74). In any case, the correlation between macrophage density 
and patient survival is less significant than that of T cells, particu-
larly CD8+ T cells (18), and it has been proposed that clinical out-
come could be better predicted by the ratio of the densities of CD8+ 
T cells/macrophages (75, 76). In contrast, a high density of mature 
DCs is generally associated with longer survival, as in NSCLC (77), 
breast cancer (78), or melanoma (78), although the density of mye-
loid cells expressing the DC-lysosomal–associated membrane pro-
tein (LAMP) marker was found to correlate with shorter survival in 
RCC (41, 79). In a mouse model of ovarian cancer, it was shown that 
phenotypically divergent DCs drive both immunosurveillance and 
accelerated tumor growth (80). The switch from one phenotype to 
the other coincided with an increasingly immunosuppressed tumor 
microenvironment. In addition to macrophages and DCs, emerging 
data have revealed a role of neutrophil extracellular traps (NETs) 
in cancer immunoediting. These are neutrophil-derived structures 
composed of extruded DNA, decorated with antimicrobial proteins. 
Although they are generally formed in response to infectious stim-
uli, they have been reported to sequester circulating tumor cells and 
promote metastases (81, 82).
CD4+ T cell subsets. Compared with myeloid cells, the effects 
of T cell subsets in the tumor/immune microenvironment appear 
much less straightforward (16). The Th2 signature correlated with 
favorable prognosis in Hodgkin lymphoma (83) and breast can-
cer (84), but shorter survival in ovarian (85), pancreatic (86), and 
gastric cancers (87). Conversely, a Th17 signature was found to be 
deleterious in colorectal (88), lung (89), and hepatocellular car-
cinoma (90) and beneficial in ovarian (91), esophageal (92), and 
gastric (93) cancers. These findings highlight the fact that the can-
cer type may influence the clinical impact of the tumor/immune 
microenvironment on the apparent balance between Th2 and 
Th17 cells. Thus, when a Th2 signature was associated with poor 
prognosis, such as in ovarian, pancreatic, and gastric cancers, it 
was reported by independent groups that, in these cancer types, a 
Th17 signature correlated with a favorable clinical outcome. These 
observations suggest that the clinical impact of immune cell popu-
lations is highly dependent on the overall immune microenviron-
ment, which is likely orchestrated by the cancer cell type (tissue 
of origin or organ) and by the genetics of the tumor. Intratumoral 
Tregs are even more complex, since they have been reported to be 
associated with poor or favorable prognosis, not only in different 
cancer types, but also in the same cancer (94, 95). It may reflect 
the heterogeneity of Treg subsets (96) in the tumor microenviron-
ment or the selectivity of Treg markers (97).
Other immune cells. A number of other types of lymphocytes 
also contribute to the immune contexture of cancer, cancer immu-
noediting, and patient outcome. Unlike what has been observed in 
mouse models (75), high densities of B cells and T follicular helper 
(Tfh) cells correlated with longer survival in NSCLC (35), breast 
cancers (98), and CRC (18). In contrast, the impact of NK cell den-
sity is either weakly favorable (79) or null (99), depending on the 
balance of the expression of activating and inhibitory receptors 
that generally regulate the effector function of NK cells (99, 100). 
The mouse lectin-like Ly49 family receptors, which are similar to 
human killer inhibitory receptors in their capacity to bind MHC 
class I molecules, largely control the self-reactivity of NK cells. 
The importance of Ly49 in NK cell–mediated tumor immunosur-
veillance and MHC I–directed tumor editing was recently demon-
strated in a study using Ly49-deficient mice (101). Another study 
demonstrated that human tumors reduced activating NK cell 
receptor (NKp30) recognition by NK cells by shedding B7-H6 from 
their cell surface (102). Interestingly, the study observed signifi-
cantly elevated levels of soluble B7-H6 in the sera of patients with 
melanoma compared with sera of healthy donors. There is also 
interest in what prevents NK cells from entering tumors. In mice, 
a recent study reported the importance of tumor-derived IL-17D 
in recruiting NK cells into tumors (103). Interestingly, IL-17D gene 
expression was decreased in metastatic prostate tumors com-
pared with expression levels in primary prostate tumors and was 
decreased in more advanced gliomas. NK cells are generally rec-
ognized to protect mice from tumor metastasis; however, this role 
is less well established in humans. NK cell control of hematologi-
cal malignancies is an area of active interest, given that NK cells 
normally crosstalk with other lymphocytes and myeloid cells.
Cytokines, chemokines, and metabolic factors. A number of 
other soluble factors also control the composition and function 
of the cellular effectors and regulators in the tumor microenvi-
ronment. Intriguingly, a high density of CD8+ T cells correlated 
with shorter survival in RCC (79, 104), ocular melanoma (105), 
and Hodgkin lymphoma (106). Cellular and molecular analyses 
of the immune microenvironment of CRC and RCC suggest that 
the difference may be due to strong expression of immunosup-
pressive cytokines (TGF-β and IL-10), inflammatory cytokines 
(IL-6 and TNF), and angiogenic factors (VEGF) in these cancers 
(107). Notably, high levels of VEGF were also shown to negate 
the positive influence of infiltrating Th1/CD8+ T cells in ovarian 
and colorectal cancer (108, 109). In addition, evidence is now 
emerging that links hypoxia-induced angiogenesis with immune 
tolerance (110). Altered glucose metabolism (an emerging hall-
mark of cancer) (2) and acidification have also been linked with 
denaturation of IFN-γ and suppression of TNF production (111). 
In addition, recent progress in imaging technologies has high-
lighted an underappreciated role for the extracellular matrix 
(ECM) in modulating the effector function of T cells (112). A light 
reticular fiber network, rather than a dense cross-linked matrix, 
may facilitate T cell migration and immunosurveillance in the 
tumor stroma. Finally, recent studies have also uncovered a role 
for carcinoma-associated fibroblasts (CAFs) expressing fibroblast 
activation protein (FAP) and escape from immune surveillance 
through production of CXCL12 (113, 114).
The impact of the local education of T and B cells in CRC is 
enforced by the fact that in patients with tumors in which the gene 
encoding CXCL13 (a TLS-generating chemokine) was deleted, the 
tumors were less infiltrated by Tfh and B cells, and the patients 
had a shorter survival (18). IL-15 promotes lymphocyte survival 
and differentiation, and patients whose tumors had lost IL15 had 
shorter survival (115). In mice, it was shown that cutaneous tumors 
ceased CXCL9 production as a result of IFN-γ–mediated immu-
noediting (116). These tumors acquired resistance to T cell–medi-
ated immunity and were less able to recruit T and NK cells. T cell 
effector function can also be suppressed by inhibitory metabolic 
enzymes such as indolamine 2′3′-dioxygenase (IDO), an IFN-γ–
induced gene that is significantly upregulated in patients with 
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CRC-MSI, (57). Overall, these data illustrate that immune surveil-
lance of human cancers is complex and that many parameters can 
influence the effector function of CD8+ T cells.
The role of cancer immunoediting in metastases
Most studies on the immune microenvironment have been con-
ducted in primary human tumors, which are typically accessible 
by curative surgery. These studies have established that the 
patient’s immune reaction can prevent tumor invasion and partly 
control the metastatic process. Does it mean that once a metas-
tasis has been established in a distant organ, cancer has escaped 
immune surveillance? This question can begin to be approached 
by sampling metastatic sites that undergo surgery for curative or 
palliative reasons. Such samples are biased, because only opera-
ble metastases (likely the optimal cases) are analyzed; however, 
there are clearly metastases with high or low densities of TLS and 
high or low densities of T cells and DCs. In the few cases in which 
the primary tumors were also available, the immune contexture 
of the metastatic sites globally recapitulated that of the primary 
tumor (79). Patients with hepatic (117) or lung (79) metastases of 
CRC with high CD8+ T cell infiltration had a longer survival time 
than did patients with low CD8+ T cell infiltrates, while patients 
with a high infiltration of PD-1+ LAG-3+ CD8+ T cells in RCC lung 
metastases had a short survival, as was the case with the primary 
tumor (107). These observations support the concept that the type 
of immune surveillance in patients is induced early in the evolu-
tion of the disease. Operationally, it also explains the success of 
applying immunotherapeutic approaches in patients with meta-
static disease. That the malignant cells are responsible for shaping 
immune reactions is also supported by the analysis of metasta-
ses from different cancer types from the same organ, where the 
immune contexture reflects the primary tumor and not the organ 
to which these cells metastasize (32, 79).
Conclusion
Strong evidence now points to the role of cancer immunoediting 
and CD8+ T cells in sculpting cancer progression, particularly in 
those tumors displaying an adaptive resistance phenotype. By 
understanding the immune/tumor microenvironment, we can now 
target key pathways such as immune checkpoint receptors that sup-
press endogenous antitumor responses, thereby opening up new 
avenues of treatment for cancer patients. There are many key ques-
tions that must be answered in order for the field to move forward. 
These include the need to understand the immune contexture of 
patients with non–type I tumors (nonadaptive immune resistant) 
so that alternative cancer immunotherapies can be developed for 
them. In addition, the link between immune cells, vasculature, and 
other nonimmune elements (e.g., fibroblasts) needs to be better 
understood. Cancer immunoediting may cause tumor dormancy 
and/or select and promote cancer cell fitness (stem-like properties). 
Both MDSCs (118) and Th22 cells (119) have been shown to reshape 
cancer cells and contribute to cancer progression and metastases. 
Finally, more information on how cancer immunoediting occurs in 
epithelial malignancies and the types of tumor microenvironments 
they display will inform which combinations of immunotherapeu-
tic approaches should translate to the clinic.
Note added in proof. In a recently published article, Le et al. 
demonstrated that anti–PD-1 induced an objective response rate 
(ORR) of 40% in CRC-MSI patients compared with a 0% ORR in 
CRC-MSS patients (120).
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